Thryv Holdings, Inc. (NASDAQ:THRY) submitted its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a going-concern warning and ongoing strategic initiatives including a planned divestiture of its print business.
WhiteHawk Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting continued operating losses and balance sheet changes following a mid-year private placement.
The Hain Celestial Group, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting net sales of $260,274 thousand and an operating loss of $14,976 thousand for the three …
National Health Investors, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 9, 2026, reporting results for the three and nine months ended that date.
Trump Media & Technology Group Corp. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting a swing to net income of $409,749.6 thousand for the third quarter driven largely by realized and unrealized …
Crescent Capital BDC, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 9, 2026, disclosing consolidated balance sheet data and portfolio investment values as of that date.
Powerfleet, Inc. filed its quarterly report on Form 10-Q with the SEC on November 9, 2026, covering the three and six months ended September 30, 2026, disclosing continued revenue growth alongside a widening net loss attributable to common stockholders.
Paradium.AI, Inc. (formerly The Arena Group Holdings, Inc.) filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, disclosing financial results for the three and nine months ended September 30, 2026.
iHeartMedia, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 9, 2026, reporting a net loss attributable to the company of $8,804 thousand for the third quarter.
Bicara Therapeutics Inc. filed a quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission covering the period ended September 30, 2026, disclosing its financial position, risk factors, and clinical development activities centered on its lead product candidate, ficerafusp alfa.